Dr James Garner interviewed for Switzer Financial Group’s The CEO Masterclass
Our CEO, Dr James Garner sat down with Peter Switzer to discuss Kazia’s upcoming value-driving milestones in 2020 and the development of lead program, paxalisib, for Switzer Financial Group’s The CEO Masterclass series.
The interview covers:
The potential commercial opportunity for paxalisib
The unique features of the paxalisib program – how the drug has been specifically designed for brain cancer and that it crosses the blood-brain barrier
How Kazia has seen very positive signals from paxalisib throughout the clinical development program, with human data showing evidence of the drug delaying progression of the disease
The Company’s upcoming milestones in 2020, including additional data from its phase 2 trial
How the pivotal phase II / III study, GBM AGILE, will put paxalisib on a direct path to commercialisation